Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort

Rocio V. Gamboa-Cárdenas, Manuel Francisco Ugarte Gil, Massardo Loreto, Mónica P. Sacnun, Verónica Saurit, Mario H. Cardiel, Enrique R. Soriano, Cecilia Pisoni, Claudio M. Galarza-Maldonado, Carlos Rios, Sebastião C. Radominski, Geraldo da R. Castelar-Pinheiro, Washington Alves Bianchi, Simone Appenzeller, Inés Guimarães da Silveira, Cristiano A. de Freitas Zerbini, Carlo V. Caballero-Uribe, Adriana Rojas-Villarraga, Marlene Guibert-Toledano, Francisco BallesterosRubén Montufar, Janitzia Vázquez-Mellado, Jorge Esquivel-Valerio, Ignacio García De La Torre, Leonor A. Barile-Fabris, Fedra Irazoque Palezuelos, Lilia Andrade-Ortega, Pablo Monge, Raquel Teijeiro, Ángel F. Achurra-Castillo, María H. Esteva Spinetti, Graciela S. Alarcón, Bernardo A. Pons-Estel

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Objectives: To identify baseline predictors of remission and low disease activity (LDA) in early rheumatoid arthritis (RA) from the GLADAR (Grupo Latino Americano De estudio de la Artritis Reumatoide) cohort. Methods: Patients with 1- and 2-year follow-up visits were included. Remission and LDA were defined by DAS28-ESR (< 2.6 and ≤ 3.2, respectively). Baseline predictors examined were gender, ethnicity, age at diagnosis, socioeconomic status, symptoms’ duration, DMARDs, RF, thrombocytosis, anemia, morning stiffness, DAS28-ESR (and its components), HAQ-DI, DMARDs and corticosteroid use, and Sharp-VDH score. Multivariable binary logistic regression models (excluding DAS28-ESR components to avoid over adjustment) were derived using a backward selection method (α-level set at 0.05). Results: Four hundred ninety-eight patients were included. Remission and LDA/remission were met by 19.3% and 32.5% at the 1-year visit, respectively. For the 280 patients followed for 2 years, these outcomes were met by 24.3% and 38.9%, respectively. Predictors of remission at 1 year were a lower DAS28-ESR (OR 1.17; CI 1.07–1.27; p = 0.001) and HAQ-DI (OR 1.48; CI 1.04–2.10; p = 0.028). At 2 years, only DAS28-ESR (OR 1.40; CI 1.17–1.6; p < 0.001) was a predictor. Predictors of LDA/remission at 1 year were DAS28-ESR (OR 1.42; CI 1.26–1.61; p < 0.001), non-use of corticosteroid (OR 1.74; CI 1.11–2.44; p = 0.008), and male gender (OR 1.77; CI 1.2–2.63; p = 0.036). A lower baseline DAS28-ESR (OR 1.45; CI 1.23–1.70; p < 0.001) was the only predictor of LDA/remission at 2 years. Conclusions: A lower disease activity consistently predicted remission and LDA/remission at 1 and 2 years of follow-up in early RA patients from the GLADAR cohort.Key Points• In patients with early RA, a lower disease activity at first visit is a strong clinical predictor of achieving remission and LDA subsequently.• Other clinical predictors of remission and LDA to keep in mind in these patients are male gender, non-use of corticosteroids and low disability at baseline.• Not using corticosteroids at first visit is associated with a lower disease activity and predicts LDA/remission at 1 year in these patients.

Original languageEnglish
Pages (from-to)2737-2746
Number of pages10
JournalClinical Rheumatology
Issue number10
StatePublished - 1 Oct 2019
Externally publishedYes


  • Early RA outcomes
  • Early RA remission
  • Early RA response predictors
  • Latin America early RA


Dive into the research topics of 'Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort'. Together they form a unique fingerprint.

Cite this